ATE310828T1 - Implantat und vektor zur behandlung von erworbenen krankheiten - Google Patents

Implantat und vektor zur behandlung von erworbenen krankheiten

Info

Publication number
ATE310828T1
ATE310828T1 AT95930578T AT95930578T ATE310828T1 AT E310828 T1 ATE310828 T1 AT E310828T1 AT 95930578 T AT95930578 T AT 95930578T AT 95930578 T AT95930578 T AT 95930578T AT E310828 T1 ATE310828 T1 AT E310828T1
Authority
AT
Austria
Prior art keywords
implant
treatment
vector
acquired diseases
therapeutic use
Prior art date
Application number
AT95930578T
Other languages
English (en)
Inventor
Pierre Leroy
Majid Mehtali
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE310828T1 publication Critical patent/ATE310828T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95930578T 1994-09-13 1995-09-13 Implantat und vektor zur behandlung von erworbenen krankheiten ATE310828T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9410911A FR2724320B1 (fr) 1994-09-13 1994-09-13 Nouvel implant pour le traitement des maladies acquises
PCT/FR1995/001171 WO1996008574A1 (fr) 1994-09-13 1995-09-13 Nouvel implant et nouveau vecteur pour le traitement des maladies acquises

Publications (1)

Publication Number Publication Date
ATE310828T1 true ATE310828T1 (de) 2005-12-15

Family

ID=9466896

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95930578T ATE310828T1 (de) 1994-09-13 1995-09-13 Implantat und vektor zur behandlung von erworbenen krankheiten

Country Status (11)

Country Link
US (2) US6960469B2 (de)
EP (1) EP0781344B1 (de)
JP (2) JP4014628B2 (de)
AT (1) ATE310828T1 (de)
AU (1) AU3390995A (de)
CA (1) CA2199715C (de)
DE (1) DE69534633T2 (de)
DK (1) DK0781344T3 (de)
ES (1) ES2249773T3 (de)
FR (1) FR2724320B1 (de)
WO (1) WO1996008574A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016437A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
US20030157063A1 (en) * 2001-12-21 2003-08-21 Jean-Louis Touraine Gene therapy using anti-gp41 antibody and CD4 immunoadhesin
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2013134015A2 (en) * 2012-03-05 2013-09-12 Wake Forest University Health Sciences Non-viral episomal suicide construct
US20160015749A1 (en) * 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
KR20230004939A (ko) 2014-02-07 2023-01-06 맥마스터 유니버시티 3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도
JP7227630B2 (ja) 2017-10-12 2023-02-22 マックマスター ユニバーシティー Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
KR20240037892A (ko) 2021-06-01 2024-03-22 트리움비라 이뮤놀로직스 유에스에이, 인크. 클라우딘 18.2 t 세포-항원 커플러 및 이의 용도
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5831034A (en) * 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US4975369A (en) * 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
JPH04500004A (ja) * 1988-07-29 1992-01-09 ザイモジェネティクス，インコーポレイティド 真核細胞におけるポリシストロン性メッセージの高率翻訳
US5731189A (en) * 1989-02-28 1998-03-24 New York University Human monoclonal antibodies to human immunodeficiency virus
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1992015676A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Somatic cell gene therapy
HK1001832A1 (en) * 1991-04-25 1998-07-10 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
ES2173082T3 (es) * 1991-08-07 2002-10-16 W French Anderson Vectores retrovirales que contienen sitios de entrada del ribosoma internos.
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU689755B2 (en) * 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
AR003941A1 (es) * 1995-04-19 1998-09-30 Polymun Scient Immunbilogische Forschung Gmbh Anticuerpos monoclonales humanos neutralizadores de hiv-1
US6482928B1 (en) * 1999-04-13 2002-11-19 Aventis Pasteur Limited And University Of Toronto Fab′-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5

Also Published As

Publication number Publication date
US20060140920A1 (en) 2006-06-29
DK0781344T3 (da) 2006-02-13
DE69534633D1 (de) 2005-12-29
CA2199715C (fr) 2010-05-25
US6960469B2 (en) 2005-11-01
HK1002284A1 (en) 1998-08-14
WO1996008574A1 (fr) 1996-03-21
CA2199715A1 (fr) 1996-03-21
JP4014628B2 (ja) 2007-11-28
DE69534633T2 (de) 2006-08-10
AU3390995A (en) 1996-03-29
ES2249773T3 (es) 2006-04-01
JPH10505745A (ja) 1998-06-09
EP0781344A1 (de) 1997-07-02
FR2724320B1 (fr) 1996-12-20
EP0781344B1 (de) 2005-11-23
US20020107869A1 (en) 2002-08-08
JP4011604B2 (ja) 2007-11-21
JP2006320331A (ja) 2006-11-30
FR2724320A1 (fr) 1996-03-15

Similar Documents

Publication Publication Date Title
ATE209686T1 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
DK0556345T3 (da) Retrovirale vektorer,som er egnede til genterapi
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
TR199802789T2 (xx) Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
DK43890D0 (da) Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
TR199901385T2 (xx) Piperidin t�revleri.
ATE345809T1 (de) Arzneimittelzusammensetzung enthaltend tcf-ii
ATE103980T1 (de) Das f-protein vom aids-virus enthaltender impfstoff.
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
ATE276364T1 (de) Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren
DE59611330D1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0781344

Country of ref document: EP